参考文献/References:
[1].国家心血管病中心,中国心血管健康与疾病报告编写组,胡盛寿. 中国心血管健康与疾病报告2023概要[J].中国循环杂志,2024,39(7):625-660.
[2].中国血脂管理指南修订联合专家委员会. 中国血脂管理指南（2023年）[J].中国循环杂志,2023,38(3):237-271.
[3].Baratta F,Cocomello N,Coronati M,et al. Cholesterol remnants,triglyceride-rich lipoproteins and cardiovascular risk[J]. Int J Mol Sci,2023,24(5):4268.
[4].Boekholdt SM,Arsenault BJ,Mora S,et al. Association of LDL cholesterol,non–HDL cholesterol,and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins:a meta-analysis[J]. JAMA,2012,307(12):1302-1309.
[5].Borén J,Chapman MJ,Krauss RM,et al. Low‐density lipoproteins cause atherosclerotic cardiovascular disease:pathophysiological,genetic,and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel[J]. Eur Heart J,2020,41(24):2313‐2330.
[6].Jacobson TA,Ito MK,Maki KC,et al. National lipid association recommendations for patient-centered management of dyslipidemia:part 1-full report[J]. J Clin Lipidol,2015,9(2):129-169.
[7].Raja V,Aguiar C,Alsayed N,et al. Non-HDL-cholesterol in dyslipidemia:review of the state-of-the-art literature and outlook[J]. Atherosclerosis,2023,383:117312.
[8].Ference BA,Ginsberg HN,Graham I,et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic,epidemiologic,and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel[J].?Eur Heart J,2017,38(32):2459-2472.
[9].Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease:new insights from epidemiology,genetics,and biology[J]. Circ Res,2016,118(4):547-563.
[10].中国中西医结合学会检验医学专业委员会. 非传统血脂指标与动脉粥样硬化性心血管疾病风险管理中国专家共识[J]. 中华预防医学杂志,2022,56(4):405-421.
[11].Linton MF,Yancey PG,Tao H,et al. HDL function and atherosclerosis:reactive dicarbonyls as promising targets of therapy[J]. Circ Res,2023,132(11):1521-1545.
[12].Johannesen CDL,Mortensen MB,Langsted A,et al. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients[J]. J Am Coll Cardiol,2021,77(11):1439-1450.
[13].Hansen MK,Mortensen MB,Olesen KKW,et al. Non-HDL cholesterol and residual cardiovascular risk in statin-treated patients with and without diabetes:the Western Denmark Heart Registry[J]. Eur J Prev Cardiol,2024,31(10):1238-1248.
[14].Hodkinson A,Tsimpida D,Kontopantelis E,et al. Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease:systematic review and network meta-analysis[J]. BMJ,2022,376:e067731.
[15].Tan MY,Weng L,Yang ZH,et al. The association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio with type 2 diabetes mellitus:recent findings from NHANES 2007-2018[J]. Lipids Health Dis,2024,23(1):151.
[16].Huang X,Li J,Zhang L,et al. The association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and non-alcoholic fatty liver disease in US adults:a cross-sectional study[J]. Sci Rep,2024,14(1):24847.
[17].Jiang Z,Zhu X,Zhao D,et al. Associations between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and hyperuricemia:a cross-sectional study[J]. Lipids Health Dis,2024,23(1):280.
[18].Kim SW,Jee JH,Kim HJ,et al. Non-HDL-cholesterol/HDL-cholesterol is a better predictor of metabolic syndrome and insulin resistance than apolipoprotein B/apolipoprotein A1[J]. Int J Cardiol,2013,168(3):2678-2683.
[19].Yu B,Li M,Yu Z,et al. The non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio(NHHR) as a predictor of all-cause and cardiovascular mortality in US adults with diabetes or prediabetes:NHANES 1999-2018[J]. BMC Med,2024,22(1):317.
[20].Zhao Z,Wang H,Hou Q,et al. Non-traditional lipid parameters as potential predictors of carotid plaque vulnerability and stenosis in patients with acute ischemic stroke[J]. Neurol Sci,2023,44(3):835-843.
[21].Liu J,Oorloff MD,Nadella A,et al. Association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio(NHHR) and cardiovascular outcomes in patients undergoing percutaneous coronary intervention:a retrospective study[J]. Lipids Health Dis,2024,23(1):324.
[22].Gao P,Zhang J,Fan X. NHHR:an important independent risk factor for patients with STEMI[J]. Rev Cardiovasc Med, 2022 ,23(12):398.
[23].Toprak K,Karata? M ,Kaplangoray M,et al. Comparison of the effect of non-HDL-C/HDL-C ratio on coronary slow flow with other non-traditional lipid markers[J]. Acta Cardiol Sin,2024,40(4):388-401.
[24].Song P,Fang Z,Wang H,et al. Global and regional prevalence,burden,and risk factors for carotid atherosclerosis:a systematic review,meta-analysis,and modelling study[J]. Lancet Glob Health,2020,8(5):e721-e729.
[25].Liu Y,Zhang Z,Xia B,et al. Relationship between the non-HDLc-to-HDLc ratio and carotid plaques in a high stroke risk population:a cross-sectional study in China[J]. Lipids Health Dis,2020,19(1):168.
[26].Wang A,Li Y,Zhou L,et al. Non-HDL-C/HDL-C ratio is associated with carotid plaque stability in general population:a cross-sectional study [J]. Front Neurol,2022,13:875134.
[27].Iannuzzi A,Giallauria F,Gentile M,et al. Association between non-HDL-C/HDL-C ratio and carotid intima-media thickness in post-menopausal women[J]. J Clin Med,2021,11(1):78.
[28].Masson W,Epstein T,Huerín M,et al. Association between non-HDL-C/HDL-C ratio and carotid atherosclerosis in postmenopausal middle-aged women[J]. Climacteric,2019,22(5):518-522.
[29].Shaya GE,Leucker TM,Jones SR,et al. Coronary heart disease risk:low-density lipoprotein and beyond[J].?Trends Cardiovasc Med,2022,32(4):181-194.
[30].You J,Wang Z,Lu G,et al. Association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and the risk of coronary artery disease[J]. Biomed Res Int,2020,2020:7146028.
[31].Li Y,Feng Y,Li S,et al. The atherogenic index of plasma(AIP) is a predictor for the severity of coronary artery disease[J]. Front Cardiovasc Med,2023,10:1140215.
[32].Li Y,Chen X,Li S,et al. Non-high-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio serve as a predictor for coronary collateral circulation in chronic total occlusive patients[J]. BMC Cardiovasc Disord,2021,21(1):311.
[33].Ma Q,Li R,Wang L,et al. Temporal trend and attributable risk factors of stroke burden in China,1990-2019:an analysis for the Global Burden of Disease Study 2019[J].Lancet Public Health,2021,6(12):e897-e906.
[34].Wang L,Han Y,Cao C,et al. The non-linear link between non-high-density lipoprotein to high-density lipoprotein ratio and the risk of stroke in middle-aged and older adults in Chinese:a prospective cohort study from the China health and retirement longitudinal study[J]. Front Endocrinol (Lausanne),2024,14:1303336.
[35].Liu Z,Lin X,Zeng L,et al. Elevated non-HDL-C/HDL-C ratio increases the 1-year risk of recurrent stroke in older patients with non-disabling ischemic cerebrovascular events:results from the Xi’an Stroke Registry Study of China[J]. BMC Geriatr,2023,23(1):410.
相似文献/References:
[1]史云聪 郭艺芳.2型糖尿病和动脉粥样硬化性心血管疾病的关系[J].心血管病学进展,2020,(5):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
SHI Yuncong,GUO Yifang.Relationship Between Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(6):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
[2]李艳茹,白世茹,李如意,等.PCSK9抑制剂在血脂代谢中的研究进展[J].心血管病学进展,2020,(7):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
LI Yanru,BAI Shiru,LI Ruyi,et al.PCSK9 Inhibitors in Lipid Metabolism[J].Advances in Cardiovascular Diseases,2020,(6):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
[3]马晓磊 朱国斌.Wnt信号与动脉粥样硬化性心血管疾病研究进展[J].心血管病学进展,2020,(8):855.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.018]
MA Xiaolei,ZHU Guobin.Wnt Signaling and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(6):855.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.018]
[4]黄毕.慢性肾脏病合并动脉粥样硬化性心血管疾病的调脂治疗进展[J].心血管病学进展,2020,(10):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
HUANG Bi.Lipid Management in Patients with Chronic Kidney Disease and Arteriosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(6):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
[5]姚雅洁 蔡恒.PCSK9抑制剂Evolocumab动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2020,(12):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
YAO Yajie,CAI Heng.PCSK9 Inhibitor Evolocumab and ASCVD[J].Advances in Cardiovascular Diseases,2020,(6):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
[6]曹岩 颜培实.残余胆固醇与动脉粥样硬化性心血管疾病[J].心血管病学进展,2021,(10):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]
CAO Yan,YAN Peishi.Remnant Cholesterol And Atherosclerotic?ardiovascular Disease[J].Advances in Cardiovascular Diseases,2021,(6):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]
[7]蔡薇 杨堰焯 刘昊凌.甘油三酯葡萄糖乘积指数与糖尿病血管病变的研究进展[J].心血管病学进展,2022,(3):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
CAI Wei,YANG Yanzhuo,LIU Haoling.Triglyceride-Glucose Index and Diabetic Vascular Disease[J].Advances in Cardiovascular Diseases,2022,(6):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[8]陈林滔 田清平 刘梅林.残余胆固醇预测动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2022,(6):492.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.004]
CHEN Lintao,TIAN Qingping,LIU Meilin.Remnant Cholesterol in Predicting Atherosclerotic Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2022,(6):492.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.004]
[9].胆固醇酯转移蛋白抑制剂在动脉粥样硬化性心血管疾病治疗中的研究进展[J].心血管病学进展,2022,(7):600.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
ZHU Jie,GAO Fen,XUE Shuanqin,et al.Treatment of Atherosclerotic Cardiovascular Diseases with Cholesteryl Ester Transfer Protein Inhibitor[J].Advances in Cardiovascular Diseases,2022,(6):600.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[10]欧阳运峰 李皇庆 李璐 阳军.脂蛋白a：动脉粥样硬化性心血管疾病防治新靶点[J].心血管病学进展,2022,(8):731.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.016]
OUYANG Yunfeng,LI Huangqing,LI Lu,et al.Lipoprotein A:a New Target for Prevention and Treatment of Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2022,(6):731.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.016]